Philadelphia, PA (May 28, 2020) – Oncoceutics, Inc. announced that it and its collaborators will present several abstracts at the virtual 2020 Annual Meeting of the American Society of Clinical Oncology (ASCO) from Friday, May 29th to Tuesday, June 2nd that highlight the clinical safety and efficacy of ONC201 across a number of clinical trials,
Philadelphia, PA (May 19, 2020) – Oncoceutics, Inc. announced that the latest research findings with ONC201 and its novel class of imipridones will be presented at the 2020 annual meeting of the American Association of Cancer Research (AACR) on June 22-24, 2020. The research presented at AACR highlights the antitumor and cancer prevention activity of
Philadelphia, PA (May 5, 2020) – Oncoceutics, a clinical-stage drug discovery and development company, commemorates Brain Tumor Awareness Month this May and expresses its support for all those affected by brain tumors. Brain tumors remain one of the greatest current health challenges as there are limited treatment options for patients, and prognoses continue to be
Philadelphia, PA (April 7, 2020) – Oncoceutics, Inc., a clinical-stage drug discovery and development company with a novel class of compounds called imipridones, announced today that Wolfgang Oster, MD, PhD, one of the company’s co-founders and Chief Executive Officer, has left the company effective April 3 as part of a leadership change. He has also
Business Development